RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma
Sponsor: MacroGenics
Listed as NCT00101972, this PHASE1 trial focuses on Cancer and remains completed. Sponsored by MacroGenics, it has been updated 8 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MacroGenics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Miami, United States
- • Nashville, United States
- • Philadelphia, United States
- • Santa Monica, United States
- • Washington D.C., United States